Table 4.
Overall hazard assessment of donor cancer type on recipient survival.
| Donor cancer types | Patient survival | Graft survival | Cancer-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Kidney transplantation | |||||||||
| No cancer | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – |
| CNS cancer | 1.18 | 0.99–1.40 | 0.06 | 1.14 | 1.00–1.30 | 0.06 | 0.67 | 0.49–0.93 | 0.02 |
| Non-melanoma skin cancer | 1.09 | 0.98–1.22 | 0.11 | 1.04 | 0.96–1.14 | 0.34 | 1.22 | 1.05–1.42 | 0.01 |
| Melanoma | 1.09 | 0.81–1.47 | 0.57 | 0.96 | 0.75–1.23 | 0.75 | 0.79 | 0.47–1.31 | 0.35 |
| Genitourinary cancer | 1.20 | 1.04–1.38 | 0.01 | 1.25 | 1.13–1.39 | 0.00 | 0.92 | 0.73–1.16 | 0.47 |
| Thyroid cancer | 1.00 | 0.65–1.55 | 1.00 | 0.89 | 0.621.26 | 0.51 | 1.41 | 0.82–2.44 | 0.21 |
| Hematologic malignancy | 0.89 | 0.45–1.78 | 0.74 | 1.22 | 0.78–1.92 | 0.38 | 0.00 | – | 0.56 |
| Lung cancer | 2.54 | 1.06–6.10 | 0.04 | 1.78 | 0.80–3.96 | 0.16 | 1.29 | 0.18–9.16 | 0.80 |
| Otorhinolaryngologic cancer | 0.67 | 0.28–1.60 | 0.37 | 0.56 | 0.27–1.17 | 0.12 | 0.98 | 0.32–3.05 | 0.98 |
| Breast cancer | 0.96 | 0.73–1.26 | 0.76 | 1.03 | 0.84–1.26 | 0.80 | 0.93 | 0.621.41 | 0.75 |
| Gastrointestinal cancer | 1.70 | 1.13–2.56 | 0.01 | 1.55 | 1.12–2.15 | 0.01 | 0.92 | 0.41–2.05 | 0.84 |
| Other, specify | 1.03 | 0.86–1.23 | 0.77 | 0.96 | 0.83–1.11 | 0.59 | 0.99 | 0.76–1.29 | 0.94 |
| Liver transplantation | |||||||||
| No cancer | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – |
| CNS cancer | 1.19 | 0.98–1.45 | 0.08 | 1.23 | 1.03–1.46 | 0.02 | 1.36 | 1.01–1.83 | 0.05 |
| Non-melanoma skin cancer | 1.10 | 0.97–1.25 | 0.14 | 1.14 | 1.02–1.28 | 0.02 | 1.19 | 0.96–1.46 | 0.11 |
| Melanoma | 1.22 | 0.83–1.79 | 0.32 | 1.21 | 0.85–1.71 | 0.29 | 0.67 | 0.28–1.60 | 0.36 |
| Genitourinary cancer | 1.01 | 0.86–1.19 | 0.86 | 1.07 | 0.93–1.23 | 0.33 | 1.38 | 1.09–1.74 | 0.01 |
| Thyroid cancer | 1.12 | 0.65–1.93 | 0.69 | 1.25 | 0.79–1.99 | 0.34 | 1.31 | 0.59–2.93 | 0.50 |
| Hematologic malignancy | 1.57 | 0.89–2.77 | 0.12 | 1.51 | 0.90–2.55 | 0.12 | 1.81 | 0.73–4.34 | 0.19 |
| Lung cancer | 1.04 | 0.39–2.76 | 0.94 | 1.05 | 0.44–2.52 | 0.92 | 2.08 | 0.67–6.46 | 0.20 |
| Otorhinolaryngologic cancer | 1.22 | 0.63–2.34 | 0.56 | 1.21 | 0.67–2.19 | 0.52 | 1.60 | 0.60–4.26 | 0.35 |
| Breast cancer | 0.96 | 0.70–1.32 | 0.78 | 1.06 | 0.81–1.38 | 0.69 | 1.51 | 0.97–2.34 | 0.07 |
| Gastrointestinal cancer | 0.51 | 0.26–1.02 | 0.06 | 1.45 | 0.24–1.87 | 0.52 | 1.04 | 0.43–2.49 | 0.94 |
| Other, specify | 1.14 | 0.93–1.40 | 0.21 | 1.18 | 0.98–1.41 | 0.08 | 0.98 | 0.48–1.42 | 0.92 |
| Heart transplantation | |||||||||
| No cancer | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – |
| CNS cancer | 1.21 | 0.91–1.62 | 0.19 | 1.20 | 0.91–1.60 | 0.20 | 1.11 | 0.78–1.59 | 0.56 |
| Non-melanoma skin cancer | 1.17 | 0.82–1.66 | 0.40 | 1.19 | 0.84–1.68 | 0.33 | 1.11 | 0.71–1.74 | 0.65 |
| Melanoma | 1.24 | 0.47–3.31 | 0.67 | 1.18 | 0.44–3.16 | 0.74 | 0.91 | 0.23–3.65 | 0.90 |
| Genitourinary cancer | 1.29 | 0.88–1.90 | 0.20 | 1.24 | 0.84–1.82 | 0.28 | 0.65 | 0.35–1.21 | 0.17 |
| Thyroid cancer | 1.15 | 0.168.16 | 0.89 | 1.10 | 0.16–7.85 | 0.92 | 7.73 | 1.92–31.04 | 0.00 |
| Hematologic malignancy | 7.06 | 2.64–18.90 | 0.00 | 6.71 | 2.51–17.94 | 0.00 | 0.00 | – | 0.93 |
| Otorhinolaryngologic cancer | 8.29 | 1.17–58.92 | 0.03 | 8.03 | 1.13–57.08 | 0.04 | 0.00 | – | 1.00 |
| Breast cancer | 2.81 | 0.91–8.72 | 0.07 | 2.67 | 0.86–8.29 | 0.09 | 0.00 | – | 0.91 |
| Gastrointestinal cancer | 2.29 | 0.57–9.18 | 0.24 | 2.20 | 0.558.82 | 0.26 | 0.00 | – | 0.92 |
| Other, specify | 1.14 | 0.72–1.81 | 0.59 | 1.08 | 0.681.72 | 0.73 | 1.11 | 0.63–1.96 | 0.71 |
HR – hazard ratio; 95% CI – 95% confidence interval.